IL13 and systemic sclerosis: Nonetheless, it has valuable translational potential, as the Fra-2 TG mouse model closely resembles human SSc-ILD and has been successfully used to assess the efficacy of nintedanib, recently approved for the treatment of SSc-ILD, or IL-13 blocking antibodies [16, 21, 23].